NantCapital

ImmunityBio, Inc. is an immunotherapy company focused on developing innovative treatments that enhance the body's immune response to combat various cancers without relying on high-dose chemotherapy. The company's product pipeline includes a memory T-cell cancer vaccine, albumin-linked chemotherapeutics, a novel IL-15 cytokine superagonist known as Anktiva, checkpoint inhibitors, and various vaccine therapies targeting specific tumor-associated antigens. Incorporated in 2014 and headquartered in El Segundo, California, ImmunityBio aims to address multiple tumor types, including bladder, lung, and colorectal cancers, as well as glioblastoma. The company is a subsidiary of NantWorks, LLC, and is actively engaged in clinical development to bring its next-generation immuno- and cellular therapies to market.

ImmunityBio, Inc. is an immunotherapy company focused on developing innovative treatments that enhance the body's immune response to combat various cancers without relying on high-dose chemotherapy. The company's product pipeline includes a memory T-cell cancer vaccine, albumin-linked chemotherapeutics, a novel IL-15 cytokine superagonist known as Anktiva, checkpoint inhibitors, and various vaccine therapies targeting specific tumor-associated antigens. Incorporated in 2014 and headquartered in El Segundo, California, ImmunityBio aims to address multiple tumor types, including bladder, lung, and colorectal cancers, as well as glioblastoma. The company is a subsidiary of NantWorks, LLC, and is actively engaged in clinical development to bring its next-generation immuno- and cellular therapies to market.

NantHealth is a healthcare company focused on enhancing diagnostics and clinical delivery through the integration of science and technology. It offers an evidence-based platform designed to empower physicians, patients, payers, and researchers by breaking down traditional barriers in the healthcare system. NantHealth develops software and hardware that collect, index, analyze, and interpret a variety of data—including molecular, financial, clinical, and operational information—to improve decision-making in patient care. The company's solutions are particularly aimed at cancer care and aim to provide personalized, genomically-informed approaches to healthcare, ultimately promoting wellness and supporting the development of next-generation healthcare solutions.

ImmunityBio, Inc. is an immunotherapy company focused on developing innovative treatments that enhance the body's immune response to combat various cancers without relying on high-dose chemotherapy. The company's product pipeline includes a memory T-cell cancer vaccine, albumin-linked chemotherapeutics, a novel IL-15 cytokine superagonist known as Anktiva, checkpoint inhibitors, and various vaccine therapies targeting specific tumor-associated antigens. Incorporated in 2014 and headquartered in El Segundo, California, ImmunityBio aims to address multiple tumor types, including bladder, lung, and colorectal cancers, as well as glioblastoma. The company is a subsidiary of NantWorks, LLC, and is actively engaged in clinical development to bring its next-generation immuno- and cellular therapies to market.

ImmunityBio, Inc. is an immunotherapy company focused on developing innovative treatments that enhance the body's immune response to combat various cancers without relying on high-dose chemotherapy. The company's product pipeline includes a memory T-cell cancer vaccine, albumin-linked chemotherapeutics, a novel IL-15 cytokine superagonist known as Anktiva, checkpoint inhibitors, and various vaccine therapies targeting specific tumor-associated antigens. Incorporated in 2014 and headquartered in El Segundo, California, ImmunityBio aims to address multiple tumor types, including bladder, lung, and colorectal cancers, as well as glioblastoma. The company is a subsidiary of NantWorks, LLC, and is actively engaged in clinical development to bring its next-generation immuno- and cellular therapies to market.

Heliogen, Inc. is a clean energy technology company based in Pasadena, California, founded in 2013. It specializes in using concentrated solar power to produce renewable fuels such as hydrogen and syngas, aiming to eliminate reliance on fossil fuels in heavy industry. The company has developed innovative systems, including HelioMax, a closed-loop control system for electricity generation and process heat applications, and HelioHeat, which provides carbon-free, ultra-high-temperature heat for sectors like cement, refining, and mining. Heliogen’s AI-enabled modular technology enables the cost-effective delivery of continuous carbon-free energy in the form of heat, power, or green hydrogen, marking a significant advancement in sustainable energy solutions.

PacketFabric, Inc. operates a Network-as-a-Service platform that offers Ethernet-based cloud networking services. Founded in 2015 and headquartered in Culver City, California, the company provides a private layer 2 network designed for secure and scalable connectivity among colocation facilities, major cloud providers, and Internet exchanges. Its platform enables businesses to procure, manage, and control their network connectivity while emphasizing security and cost-effectiveness. By utilizing automated software-defined networking and advanced optical and packet-switching technologies, PacketFabric facilitates dynamic, real-time connectivity services on a terabit scale. All services are accessible through the company's user-friendly portal and API, allowing enterprises to efficiently manage their data transfer needs.

Benitec Biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases. Their transformational technology, ddRNAi, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. Compared to traditional approaches to RNA intereference, ddRNAi is easier to deliver, safer to us, more targeted and more efficient. Benitec has a pipeline of in-house and partnered drug development programs based on ddRNAI, including Hepatitis C and B, cancer-associated pain and drug-resistant lung cancer. Our Hepatitis C program is nearing clinical trials in 2013. ddRNAi has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. The technology is available from Benitec under a variety of licence options.

Veradigm provides health industry software. The company is based in Chicago, Illinois. Allscripts, LLC was formerly a subsidiary of Allscripts Healthcare Solutions Inc. As a result of the acquisition of Allscripts Healthcare Solutions Inc. by Allscripts-Misys Healthcare Solutions, Inc. as of October 10, 2008, Allscripts, LLC operates as a subsidiary of Allscripts-Misys Healthcare Solutions, Inc.